References
- Bonjoch A, Figueras M, Estany C, et al. Osteoporosis Study Group. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS. 2010;24(18):2827–2833.
- Gonciulea A, Wang R, Althoff KN, et al. An increased rate of fracture occurs a decade earlier in HIV + compared with HIV- men ). AIDS. 2017;31(10):1435–1443.
- Annapoorna N, Rao G, Reddy NS, Rambabu P, Rao KR. An increased risk of osteoporosis during acquired immunodeficiency syndrome. Int J Med Sci. 2004;1(3):152–164.
- Hileman CO, Eckard AR, McComsey GA. Bone loss in HIV: a contemporary review. Curr Opin Endocrinol Diabetes Obes. 2015;22(6):446–451.
- Madeddu G, Spanu A, Solinas P, et al. Different impact of NNRTI and PI-including HAART on bone mineral density loss in HIV-infected patients. Eur Rev Med Pharmacol Sci. 2015;19(23):4576–4589.
- Post FA. Bone mineral density decline in patients on stable antiretroviral therapy. AIDS. 2017;31(5):727–729.
- McGinty T, Mirmonsef P, Mallon PW, Landay AL. Does systemic inflammation and immune activation contribute to fracture risk in HIV? Curr Opin HIV AIDS. 2016;11(3):253–260.
- Pietschmann P, Mechtcheriakova D, Meshcheryakova A, Föger-Samwald U, Ellinger I. Immunology of osteoporosis: a mini-review. Gerontology. 2016;62(2):128–137.
- de Menezes EG, Machado AA, Barbosa F, Jr, de Paula FJ, Navarro AM. Bone metabolism dysfunction mediated by the increase of proinflammatory cytokines in chronic HIV infection. J Bone Miner Metab. 2017;35(2):234–242.
- Hoffman RM, Lake JE, Wilhalme HM, Tseng CH, Currier JS. Vitamin D levels and markers of inflammation and metabolism in HIV-infected individuals on suppressive antiretroviral therapy. AIDS Res Hum Retroviruses. 2016;32(3):247–254.
- Peters BS, Wierzbicki AS, Moyle G, Nair D, Brockmeyer N. The effect of 12-week course of omega-3 polyunsaturated fatty acids on lipid parameters in hypertriglyceridemic adult HIV-infected patients undergoing HAART: a randomized, placebo-controlled pilot trial. Clin Ther. 2012;34(1):67–76.
- Thusgaard M, Christensen JH, Mørn B, et al. Effect of fish oil (n-3 polyunsaturated fatty acids) on plasma lipids, lipoproteins and inflammatory markers in HIV-infected patients treated with antiretroviral therapy: a randomized, double-blind, placebo-controlled study. Scand J Infect Dis. 2009;41(10):760–766.
- Orchard TS, Pan X, Cheek F, Ing SW, Jackson RD. A systematic review of omega-3 fatty acids and osteoporosis. Br J Nutr. 2012;107(Suppl 2):S253–S260.
- Rajaei E, Mowla K, Ghorbani A, Bahadoram S, Bahadoram M, Dargahi-Malamir M. The effect of omega-3 fatty acids in patients with active rheumatoid arthritis receiving DMARDs therapy: double-blind randomized controlled trial. Glob J Health Sci. 2015;8(7):18–25.
- Huang J, Meixner L, Fernandez S, McCutchan JA. A double-blinded, randomized controlled trial of zolendronate therapy for HIV-associated osteopenia and osteoporosis. AIDS. 2009;23(1):51–57.
- Chen JS, Hill CL, Lester S, et al. Supplementation with omega-3 fish oil has no effect on bone mineral density in adults with knee osteoarthritis: a 2-year randomized controlled trial. Osteoporos Int. 2016;27(5):1897–1905.
- Bassey EJ, Littlewood JJ, Rothwell MC, Pye DW. Lack of effect of supplementation with essential fatty acids on bone mineral density in healthy pre- and postmenopausal women: two randomized controlled trials of Efacal v. calcium alone. Br J Nutr. 2000;83(6):629–635.
- European AIDS Clinical Society. Clinical Guide. European AIDS Clinical Society (EACS). 2017.